{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:00:27Z","timestamp":1794492027840,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T00:00:00Z","timestamp":1277769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1245\/s10434-010-1182-1","type":"journal-article","created":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T12:11:51Z","timestamp":1277727111000},"page":"3336-3343","source":"Crossref","is-referenced-by-count":62,"title":["Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer"],"prefix":"10.1245","volume":"17","author":[{"given":"Kathrin","family":"Mutze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Novotny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Luber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hapfelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"G\u00f6ttlicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"H\u00f6fler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,29]]},"reference":[{"key":"1182_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1182_CR2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10120-005-0321-z","volume":"8","author":"F Lordick","year":"2005","unstructured":"Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer. 2005;8:78\u201385.","journal-title":"Gastric Cancer"},{"key":"1182_CR3","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420\u201332.","journal-title":"Oncogene"},{"key":"1182_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2009.10.011","volume":"625","author":"LS Kristensen","year":"2009","unstructured":"Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol. 2009;625:131\u201342.","journal-title":"Eur J Pharmacol"},{"key":"1182_CR5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683\u201392.","journal-title":"Cell"},{"key":"1182_CR6","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1158\/1078-0432.CCR-07-0241","volume":"13","author":"R Napieralski","year":"2007","unstructured":"Napieralski R, Ott K, Kremer M, et al. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res. 2007;13:5095\u2013102.","journal-title":"Clin Cancer Res"},{"key":"1182_CR7","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003;63:7291\u2013300.","journal-title":"Cancer Res"},{"key":"1182_CR8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1349-7006.2008.00793.x","volume":"99","author":"CT Lin","year":"2008","unstructured":"Lin CT, Lai HC, Lee HY, et al. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008;99:1218\u201326.","journal-title":"Cancer Sci"},{"key":"1182_CR9","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/nar\/28.15.2954","volume":"28","author":"NP Davies","year":"2000","unstructured":"Davies NP, Hardman LC, Murray V. The effect of chromatin structure on cisplatin damage in intact human cells. Nucleic Acids Res. 2000;28:2954\u20138.","journal-title":"Nucleic Acids Res"},{"key":"1182_CR10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","volume":"9","author":"W Weichert","year":"2008","unstructured":"Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139\u201348.","journal-title":"Lancet Oncol"},{"key":"1182_CR11","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-07-0990","volume":"14","author":"W Weichert","year":"2008","unstructured":"Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14:1669\u201377.","journal-title":"Clin Cancer Res"},{"key":"1182_CR12","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-08-2319","volume":"15","author":"J Suzuki","year":"2009","unstructured":"Suzuki J, Chen YY, Scott GK, et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res. 2009;15:3163\u201371.","journal-title":"Clin Cancer Res"},{"key":"1182_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"1182_CR14","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(20010301)91:5<918::AID-CNCR1081>3.0.CO;2-W","volume":"91","author":"CP Schuhmacher","year":"2001","unstructured":"Schuhmacher CP, Fink U, Becker K, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5\u00a0years of follow-up. Cancer. 2001;91:918\u201327.","journal-title":"Cancer"},{"key":"1182_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10120-003-0245-4","volume":"6","author":"K Ott","year":"2003","unstructured":"Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003;6:159\u201367.","journal-title":"Gastric Cancer"},{"key":"1182_CR16","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1200\/JCO.2003.06.574","volume":"21","author":"K Ott","year":"2003","unstructured":"Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604\u201310.","journal-title":"J Clin Oncol"},{"key":"1182_CR17","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.ejca.2009.09.021","volume":"45","author":"G Stocker","year":"2009","unstructured":"Stocker G, Ott K, Henningsen N, et al. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer. 2009;45:3326\u201335.","journal-title":"Eur J Cancer"},{"key":"1182_CR18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521\u201330.","journal-title":"Cancer"},{"key":"1182_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"1182_CR20","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ijc.21570","volume":"118","author":"B Gyorffy","year":"2006","unstructured":"Gyorffy B, Surowiak P, Kiesslich O, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006;118:1699\u2013712.","journal-title":"Int J Cancer"},{"key":"1182_CR21","first-page":"3578","volume":"9","author":"WK Kelly","year":"2003","unstructured":"Kelly WK, Richon VM, O\u2019Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9:3578\u201388.","journal-title":"Clin Cancer Res"},{"key":"1182_CR22","doi-asserted-by":"crossref","unstructured":"Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8:381.","DOI":"10.1186\/1471-2407-8-381"},{"key":"1182_CR23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275\u201384.","journal-title":"Nat Rev Cancer"},{"key":"1182_CR24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrg1748","volume":"7","author":"AP Feinberg","year":"2006","unstructured":"Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7:21\u201333.","journal-title":"Nat Rev Genet"},{"key":"1182_CR25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","volume":"5","author":"P Zhu","year":"2004","unstructured":"Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5:455\u201363.","journal-title":"Cancer Cell"},{"key":"1182_CR26","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1158\/1535-7163.MCT-06-0419","volume":"5","author":"JH Lee","year":"2006","unstructured":"Lee JH, Park JH, Jung Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther. 2006;5:3085\u201395.","journal-title":"Mol Cancer Ther"},{"key":"1182_CR27","doi-asserted-by":"crossref","unstructured":"Owonikoko TK, Ramalingam SS, Kanterewicz B, et al. Vorinostat increases carboplatin and paclitaxel activity in non\u2013small cell lung cancer cells. Int J Cancer. 126:743\u201355.","DOI":"10.1002\/ijc.24759"},{"key":"1182_CR28","first-page":"563","volume":"16","author":"X Zhang","year":"2006","unstructured":"Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep. 2006;16:563\u20138.","journal-title":"Oncol Rep"},{"key":"1182_CR29","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1242\/jcs.02689","volume":"118","author":"SM Gorisch","year":"2005","unstructured":"Gorisch SM, Wachsmuth M, Toth KF, et al. Histone acetylation increases chromatin accessibility. J Cell Sci. 2005;118:5825\u201334.","journal-title":"J Cell Sci"},{"key":"1182_CR30","doi-asserted-by":"crossref","unstructured":"Dejligbjerg M, Grauslund M, Litman T, et al. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer. 2008;7:70.","DOI":"10.1186\/1476-4598-7-70"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-010-1182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-010-1182-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-010-1182-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:38:07Z","timestamp":1572953887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-010-1182-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,29]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1245\/s10434-010-1182-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,29]]}}}